

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133		SERIAL NO.: <del>09/701,904</del> 10/700,906										
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.												
				FILING DATE: <del>February 8, 2004</del> 11/4/03		GROUP: 1615										
<b>U.S. PATENT DOCUMENTS</b>																
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE			
HS	AA	3	9	6	5	2	5	6	06/22/1976	Leslie	424	22				
	AB	4	2	3	7	1	4	0	12/02/1980	Dudzinski	424	260				
	AC	4	3	6	6	3	1	0	12/28/1982	Leslie	536	56				
	AD	4	4	4	3	4	2	8	04/17/1984	Oshlack, et al.	424	22				
	AE	4	8	2	8	8	3	6	05/09/1989	Elger, et al.	424	419				
	AF	4	8	3	4	9	6	5	05/30/1989	Martani, et al.	424	488				
	AG	4	8	3	4	9	8	4	05/30/1989	Goldie, et al.	424	488				
	AH	4	8	3	4	9	8	5	05/30/1989	Elger, et al.	424	488				
	AI	4	8	4	4	9	0	7	07/04/1989	Elger, et al.	424	465				
HS	AJ	4	8	4	4	9	0	9	07/04/1989	Goldie, et al.	424	480				
<b>FOREIGN PATENT DOCUMENTS</b>																
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION			
													YES	NO		
HS	AK	0	1	9	3	3	5	5	09/03/1986	Europe (A3)	A61K	31/615				
HS	AL	0	3	1	9	2	4	3	06/07/1989	Europe (A1)	A61K	31/485				
HS	AM	0	3	1	9	2	4	3	11/07/1990	Europe (A2)	A61K	31/485				
HS	AN	0	0	0	1	3	7	7	01/13/2000	WO	A61K	31/00				
HS	AO	9	0	0	4	9	6	5	05/17/1990	WO	A61K	31/485				
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>																
HS	AP	Translation of previously submitted German patent application DE 43 25 465 (2003)														
HS	AQ	Alvarez-Fuentes, et al., "Effectiveness of Repeated Administration of a New Oral Naltrexone Controlled-Release System on Morphine Analgesia"; J. Pharm Pharmacol (2001), 53; pg. 1201-1205														
HS	AR	Alvarez-Fuentes, et al., "Preclinical Study of an Oral Controlled Release Naltrexone Complex in Mice"; J. Pharm Pharmacol (2000), 52; pg. 659-663														
EXAMINER										/Humera Sheikh/					DATE CONSIDERED	
															01/21/2007	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.																

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133		SERIAL NO.: 09781,081 <u>10/700,906</u>							
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.									
				FILING DATE: <del>February 8, 2001</del> <u>11/04/03</u>		GROUP: 1615							
U.S. PATENT DOCUMENTS													
EXAMINER INITIAL		DOCUMENT NUMBER			DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE				
HS	BA	4	8	4	4	9	1	0	07/04/1989	Leslie, et al.	424	494	
FOREIGN PATENT DOCUMENTS													
		DOCUMENT NUMBER			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION				
									YES	NO			
	BB												
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)													
HS	BC	Archer, Sydney; "Historical Perspective on the Chemistry and Development of Naltrexone"; Naltrexone: Research Monograph 28 (1980) pg. 3-9											
	BD	Baum, et al., "The Impact of the Addition of Naloxone on the Use and Abuse of Pentazocine"; Public Health Reports (1987) Vol. 102, No. 4 pg. 426-429											
	BE	Rapaka, et al., "Discovery of Novel Opioid Medications"; NIDA Research Monograph 147 (1995) pg. 53-83											
	BF	Bloom, et al., "Clinical Studies with Naloxone/Methadone in a Ratio of 1:20"; 5 <sup>th</sup> National Conference on Methadone Treatment (1973) Vol 2, pg. 1342 - 1349											
	BG	Blachly, M.D., "Naloxone in Opiate Addiction"; Current Psychiatric Therapies (1976) pg. 209-213											
	BH	Briscoe, et al., "Methoclocinnamox: Time Course of Changes in Alfentanil-Reinforced Responding in Rhesus Monkeys"; Psychopharmacology (2000) 148: pg. 393-399											
	BI	Abstract of Bromm, et al., "A Sensitive Method to Evaluate Effects of Analgesics in Man"; Meth and Find Exptl Clin Pharmacol 5 (8) (1983) pg. 545-551											
	BJ	Bullingham, et al., "Clinical Pharmacokinetics of Narcotic Agonist-Antagonist Drugs"; Clinical Pharm. (1983) 8: 332-343											
	BK	Calimlim, et al., "Effect of Naloxone on the Analgesic Activity of Methadone in a 1:10 Oral Combination"; Clin Pharmacol and Thera (1974) Vol. 15; No. 6 pg. 556-564											
	BL	Caruso, et al., "Methadone and Naloxone in Combination (Naldone®) for the Treatment of Heroin Addicts"; Bristol Laboratories, pg. 1336-1341F (1973)											
	BM	Cherny, Nathan I., "Opioid Analgesics"; Drugs (1996) May: 51 (5) pg. 713-737											
	BN	Chiang, et al., "Clinical Evaluation of a Naltrexone Sustained-Release Preparation"; Drug and Alcohol Dependence (1985) 16, pg. 1-8											
	BO	Chiang, et al., "Kinetics of a Naltrexone Sustained-Release Preparation"; Clin. Pharmacol Thera (1984) Vol. 36, No. 5, pg. 704-708											
↓	BP	Comer, et al., "Depot Naltrexone: Long-lasting Antagonism of the effects of heroin in humans"; Psychopharmacology (2002) 159; pg. 351-360											
HS	BQ	Crabtree, et al., "Review of Naltrexone, a long-acting opiate antagonist"; Clinical Pharmacy, Vol 3 (1984) pg. 273-280											
EXAMINER					/Humera Sheikh/			DATE CONSIDERED		01/21/2007			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133		SERIAL NO.: <del>09/781,081</del> 10/700,906		
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>  (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.		FILING DATE: February 8, 2001 <u>11/04/03</u>		
				GROUP: 1615				
<b>U.S. PATENT DOCUMENTS</b>								
*EXAMINER INITIAL	CA	DOCUMENT NUMBER				DATE	NAME	
HS		4	8	6	7	9	8	5
						09/19/1989	Heafield, et al.	
						424	461	
<b>FOREIGN PATENT DOCUMENTS</b>								
		DOCUMENT NUMBER				DATE	COUNTRY	
	CB							
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>								
HS	CC	Crain et al., "Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability"; Dept. Of Neuroscience, Albert Einstein College of Medicine, Pain 82 (1999) pg. 1-11						
	CD	Crain et al., "Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability"; Dept. Of Neuroscience, Albert Einstein College of Medicine, Pain 84 (2000) pg. 121-131						
	CE	Fink, et al., "Naloxone in Heroin Dependence"; Clin Pharm and Therapeutics, Vol 9, No. 5; pg. 568-577 (1968)						
	CF	Fishman, et al., "Disposition of Naloxone-7,8- <sup>3</sup> H in Normal & Narcotic-Dependent Men"; J. of Pharm. and Experimental Therapeutics (1973) Vol 187, No. 3, pg. 575-580						
	CG	Fraser, Albert D., et al., "Clinical Toxicology of Drugs Used in the Treatment of Opiate Dependency"; Clinical Toxicology 1, (1990) Vol 10, No. 2, pg. 375-386						
	CH	Freye, et al., "Effects of Tramadol and Tilidine/Naloxone on Oral-Caecal Transit & Pupillary Light Reflex"; Arzneim.-Forsch/Drug Res. 50 (I) (2000) pg. 24-30						
	CI	Fudala, et al., "Effects of Burpenorphine and Naloxone in Morphine-Stabilized Opioid Addicts"; Drug and Alcohol Dependence 50 (1998) pg. 1-8						
	CJ	Fudala, et al., "Human Pharmacology and Abuse Potential of Nalmefene"; Clin Pharm and Thera (1991) Vol 49, 3, pg. 300-306						
	CK	Gal, et al., "Prolonged Blockade of Opioid Effect with Oral Nalmefene"; Clin Pharmacol Ther. (1986) pg. 537-542						
	CL	Gerra, et al., "Clonidine and Opiate Receptor Antagonists in the Treatment of Heroin Addiction"; J. Substance Abuse Treatment (1995) Vol 12, 1, pg. 35-41						
	CM	Ghodse, et al., "Opioid analgesics and narcotic antagonists"; Side Effects of Drugs (2000) Annual 23, Ch. 8, pg. 96-113						
	CN	Glatt, William, M.D. FACP, "A New Method for Detoxifying Opioid-Dependent Patients"; J. Substance Abuse Treatment (1999) Vol 17, No 3, pg. 193-197						
	CO	Gold, et al., "Rapid Opioid Detoxification during General Anesthesia"; Anesthesiology (1999) Vol 91, No 6, 1639-1647						
HS	CP	Greenwald, et al., "Comparative Clinical Pharmacology of Short-Acting <i>Mu</i> Opioids in Drug Abusers"; J. Pharm. and Experimental Therapeutics (1996) Vol 277, No 3, pg. 1228-1236						
EXAMINER  /Humera Sheikh/				DATE CONSIDERED 01/21/2007				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133		SERIAL NO.: <del>09781,081</del> 10/700,906		
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.		FILING DATE: February 8, 2007 11/04/03		
				GROUP: 1615				
U.S. PATENT DOCUMENTS								
EXAMINER INITIAL	DA	DOCUMENT NUMBER				DATE	NAME	
HS		4	9	4	0	5	8	7
						07/10/1990	Jenkins, et al.	
						424	480	
FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER				DATE	COUNTRY	
	DB							
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)								
HS	DC	Gupta, et al., "Morphine Combined with Doxapram or Naloxone"; Anaesthesia (1974) Vol 29 pg. 33-39						
	DD	Richter, et al., "Clinical Investigation on the Development of Dependence during Oral Therapy with Tramadol"; Arzneim-Forsch/Drug Res. 35 (No II) (1985) pg. 1742-1744						
	DE	Rosen, et al., "Effect of Clonidine Pretreatment on Naloxone-Precipitated Opiate Withdrawal"; J. of Pharm. and Experimental Ther. (1996) Vol 276, No 3, pg. 1128-1135						
	DF	Rosen, et al., "The effect of lamotrigine on naloxone-precipitated opiate withdrawal"; Drug and Alcohol Dependence (1998) Vol 52, pg. 173-176						
	DG	Rosen, et al., "A pilot study of dextromethorphan in naloxone-precipitated opiate withdrawal"; European J. of Pharm. (1996) Vol 307, pg. 251-257						
	DH	Schuh, et al., "Buprenorphine, Morphine and Naloxone Effects during Ascending Morphine Maintenance in Humans"; J. of Pharm. and Experimental Ther. (1996) Vol 278, 2, pg. 836-846						
	DI	Schuh, et al., "Onset, magnitude and duration of opioid blockade produced by buprenorphine and naltrexone in humans"; Psychopharmacology (1999) Vol 145, pg. 162-174						
	DJ	Stevens, et al., "Nonspecific Excitatory Effects of Morphine: Reverse-Order Precipitated Withdrawal and Dose-Dose Interactions"; Psychopharmacology (1981) Vol 75, pg. 210-211						
	DK	Stine, et al., "Reduction of Opiate Withdrawal-like Symptoms by Cocaine Abuse during Methadone and Buprenorphine Maintenance"; Am. J. Drug Alcohol Abuse (1994) Vol 20, (4), pg. 445-458						
	DL	Stine, et al., "Use of Drug Combinations in Treatment of Opioid Withdrawal"; J. of Clinical Psych. (1992) Vol 12, No. 3, pg. 203-209						
	DM	Stoller, et al., "Effects of buprenorphine/naloxone in opioid-dependent humans"; Psychopharmacology (2001) Vol 154, pg. 230-242						
	DN	Strain, et al., "Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers"; J. of Pharm. and Experimental Ther. (1992) Vol 261, No. 3, pg. 985-993						
	DO	Strain, et al., "Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers"; Psychopharmacology (2000) Vol 148, pg. 374-383						
	DP	Strain, et al., "Precipitated Withdrawal by Pentazocine in Methadone-Maintained Volunteers"; J. of Pharm. and Experimental Ther. (1993) Vol 267, No 2, pg. 624-634						
	DQ	Tai, et al., "Naltrexone: An Antagonist Therapy for Heroin Addiction"; NIDA (1997) 5 pages						
HS	DR	Umbricht, et al., "Naltrexone shortened opioid detoxification with buprenorphine"; Drug and Alcohol Dependence (1999) Vol 56, pg. 181-190						
EXAMINER /Humera Sheikh/				DATE CONSIDERED 01/21/2007				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133		SERIAL NO.: 097761,081- <b>10/700,906</b>							
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.									
				FILING DATE: <del>February 8, 2001</del> <b>11/04/02</b>		GROUP: 1615							
U.S. PATENT DOCUMENTS													
*EXAMINER INITIAL	EA	DOCUMENT NUMBER				DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE			
HS	EA	4	9	7	0	0	7	5	11/13/1990	Oshlack	424	451	
FOREIGN PATENT DOCUMENTS													
		DOCUMENT NUMBER				DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION			
										YES	NO		
	EB												
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)													
HS	EC	Vaccarino, et al., "Endogenous Opiates: 1999"; Peptides 21 (2000) pg. 1975-2034											
	ED	Wang, et al., "Inverse agonists and neutral antagonists at $\mu$ opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence"; J. of Neurochemistry (2001) Vol 77, pg. 1590-1600											
	EE	Way, et al., "Responsivity to Naloxone during Morphine Dependence"; Annals New York Academy of Sciences, pg. 252-261											
	EF	Weinberg, et al., "Sublingual absorption of selected opioid analgesics"; Clin Pharm Ther (1988) Vol 44, No 3, pg. 335-342											
	EG	Wells, et al., "In Vivo Pharmacological Characterization of SoRJ 9409, a Nonpeptidic Opioid $\mu$ -Agonists/ $\delta$ -Antagonist that Produces Limited Antinociceptive Tolerance and Attenuates Morphine Physical Dependence"; J. Pharm and Exper. Thera. (2001) Vol 297, No 2, pg. 597-605											
	EH	Wodak, Alex, "Drug Treatment for Opioid Dependence"; Australian Prescriber (2001) Vol 24, No 1, pg. 4-6											
	EI	Wright, et al., "Acute physical dependence in humans; repeated naloxone-precipitated withdrawal after a single-dose of methadone"; Drug and Alcohol Dependence (1991) Vol 27, pg. 139-148											
	EJ	Zhu, et al., "Naltrexone-precipitated morphine withdrawal in infant rat is attenuated by acute administration of NOS inhibitors but not NMDA receptor antagonists"; Psychopharmacology (2000) Vol 150, pg. 325-336											
	EK	Han, et al., "Mucoadhesive buccal disks for novel nalbuphine prodrug controlled delivery: effect of formulation variables on drug release and mucoadhesive performance"; International J. of Pharm (1999) Vol 177, pg. 201-209											
	EL	Handal, et al., "Naloxone"; Annals of Emergency Medicine (1983) Vol 12:7, pg. 438-445											
	EM	Harris, et al., "Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine"; Drug and Alcohol Dependence (2000) Vol 61, pg. 85-94											
V	EN	Hawkes, et al., "Effect of an enteric-release formulation of naloxone on intestinal transit in volunteers taking codeine"; Aliment Pharm Ther (2001) Vol 15, pg. 625-630											
HS	EO	Högger, et al., "Comparison of tilidine/naloxone, tramadol and bromfenac in experimental pain: a double-blind randomized crossover study in healthy human volunteers"; International J. Clin Pharm and Ther (1999) Vol 37, No 8, pg. 377-385											
EXAMINER <b>/Humera Sheikh/</b>							DATE CONSIDERED <b>01/21/2007</b>						
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133		SERIAL NO.: <del>89781,881</del> 10/700,906								
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.										
				FILING DATE: February 6, 2004 11/04/03		GROUP: 1615								
<b>U.S. PATENT DOCUMENTS</b>														
EXAMINER INITIAL	FA	DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
HS	FA	4	9	8	7	1	3	6	01/22/1991	Kreek, et al.	514	282		
HS	FB	4	9	9	0	3	4	1	02/05/1991	Goldie, et al.	424	484		
HS	FC	5	0	7	1	6	4	6	12/10/1991	Malkowska, et al.	424	497		
HS	FD	5	0	9	1	1	8	9	02/25/1992	Heafield, et al.	424	457		
HS	FE	5	2	1	5	7	5	8	06/01/1993	Krishnamurthy	424	488		
HS	FF	5	2	2	6	3	3	1	07/13/1993	Thompson, et al.	73	865.9		
HS	FG	5	2	6	6	3	3	1	11/30/1993	Oshlack, et al.	424	468		
<b>FOREIGN PATENT DOCUMENTS</b>														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	FH													
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>														
HS	FI	Budd, Keith, "Clinical use of Opioid Antagonists"; Bailliere's Clinical Anesthesiology (1987) Vol 1, No 4, pg. 993-1011												
	FJ	Crain, et al., "Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic cotreatment"; Proc. Natl. Acad. Sci (1995) Vol 92, pg. 10540-10544												
	FK	Howes, et al., "The Pharmacology of TR5109, a New Narcotic Agonist/Antagonist Analgesic"; NIDA Research (1979) pg. 99-105												
	FL	Leeling, et al., "Disposition and metabolism of codorphone in the rat, dog and man"; Drug Metabolism and Disposition (1982) Vol 10, No 6, pg. 649-653												
	FM	Amass, et al., "Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet"; Drug and Alcohol Dependence (2000) Vol 58, pg. 143-152												
	FN	Hussain, et al., "Buccal and oral bioavailability of naloxone and naltrexone in rats"; (1987) Vol 36, pg. 127-130												
	FO	Jasinski, et al., "The human pharmacology and abuse potential of N-allylnoroxymorphone naloxone"; J. of Pharm and Exper Thera (1967) Vol 157, No. 2, pg. 420-426												
	FP	Jones, et al., "Nalmefene: blockade of intravenous morphine challenge effects in opioid abusing humans"; Drug and Alcohol Dependence (2000) Vol 60, pg. 29-37												
	FQ	Kanaf, et al., "Clinical Characteristics of Naloxone-Precipitated Withdrawal in Human Opioid-Dependent Subjects"; J. of Pharm and Exper Thera (1992) Vol 260, No. 1, pg. 355-363												
HS	FR	King, et al., "Naltrexone Biotransformation and Incidence of Subjective Side Effects: A Preliminary Study"; Alcoholism: Clin and Exp Res (1997) Vol 21, No. 5, pg. 906-909												
EXAMINER  /Humera Sheikh/										DATE CONSIDERED  01/21/2007				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133		SERIAL NO.: <del>09/781,081</del> 10/700,906								
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.										
				FILING DATE: <del>February 8, 2001</del> 11/04/03		GROUP: 1615								
U.S. PATENT DOCUMENTS														
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
HS	GA	5	2	8	6	4	9	3	02/15/1994	Oshlack, et al.	424	468		
HS	GB	5	3	2	4	3	5	1	06/28/1994	Oshlack, et al.	106	153		
HS	GC	5	3	3	6	6	9	1	08/09/1994	Raffa, et al.	514	629		
HS	GD	5	3	5	6	4	6	7	10/18/1994	Oshlack, et al.	106	153		
HS	GE	5	4	1	1	7	4	5	05/02/1995	Oshlack, et al.	424	456		
HS	GF	5	4	6	0	8	2	6	10/24/1995	Merrill, et al.	424	470		
HS	GG	5	4	7	2	7	1	2	12/05/1995	Oshlack, et al.	424	480		
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
HS	GH	8	7	0	1	2	8	2	03/12/1987	WO	A61K	31/485		
HS	GI	0	1	3	2	1	8	0	05/10/2001	WO (A2)	A61K	31/485		
HS	GJ	0	1	6	8	0	8	0	09/20/2001	WO (A2)	A61K	31/00		
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
HS	GK	Kogan, et al., "Estimation of the Systemic Availability and other Pharmacokinetic Parameters of Naltrexone in Man after Acute and Chronic Oral Administration"; Res. Comm. in Chem. Path. and Pharm (1977) Vol 18, No. 1; pg. 29-34												
HS	GL	Kosten, Thomas R., M.D., "Buprenorphine for Benzodiazepine-Abusing Heroin Addicts"; Amer J. of Psychiatry (1994) Vol 1, pg. 151												
HS	GM	Kosten, et al., "Opioid antagonist challenges in buprenorphine maintained patients"; Drug and Alcohol Dependence (1990) Vol 25, pg. 73-78												
HS	GN	Kurland, et al., "Naloxone and the Narcotic Abuser: A Controlled Study of Partial Blockade"; Inter. J. of the Addictions (1974) Vol 9, No. 5, pg. 663-672												
HS	GO	Lee, et al., "Nalbuphine Coadministered with Morphine Prevents Tolerance and Dependence"; Anesth Analg (1997) Vol 84, pg. 810-815												
HS	GP	Lehmann, et al., "Influence of Naloxone on the Postoperative Analgesic and Respiratory Effects of Buprenorphine"; Eur J. Clin. Pharm. (1988) Vol 34, 343-352												
HS	GQ	Levine, et al., "Potentiation of Pentazocine Analgesia by Low-dose Naloxone"; J Clin Invest. (1988) Vol 82, pg. 1574 - 1577												
EXAMINER /Humera Sheikh/										DATE CONSIDERED 01/21/2007				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133		SERIAL NO.: <del>09/781,081</del> 10/700,906								
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.										
				FILING DATE: <del>February 8, 2001</del> 11/04/03		GROUP: 1615								
<b>U.S. PATENT DOCUMENTS</b>														
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
HS	HA	5	4	7	8	5	7	7	12/26/1995	Sackler, et al.	424	489		
HS	HB	5	5	0	0	2	2	7	03/19/1996	Oshlack, et al.	424	476		
HS	HC	5	5	0	8	0	4	2	04/16/1996	Oshlack, et al.	424	468		
HS	HD	5	5	0	8	0	4	3	04/16/1996	Krishnamurthy	424	484		
HS	HE	5	5	4	9	9	1	2	08/27/1996	Oshlack, et al.	424	468		
HS	HF	5	5	5	2	4	2	2	09/03/1996	Gauthier, et al.	514	368		
HS	HG	5	5	9	1	4	5	2	01/07/1997	Miller, et al.	424	468		
HS	HH	5	6	0	1	8	4	5	02/11/1997	Buxton, et al.	424	495		
HS	HI	5	6	2	2	7	2	2	04/22/1997	Knott, et al.	424	494		
HS	HJ	5	6	3	9	4	7	6	06/17/1997	Oshlack, et al.	424	468		
<b>FOREIGN PATENT DOCUMENTS</b>														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	HK													
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>														
HS	HL	Loimer, et al., "Combined Naloxone/Methadone Preparations for Opiate Substitution Therapy"; J. of Substance Abuse Treatment (1991) Vol 8, pg. 157-160												
HS	HM	Martin, et al., "Bioavailability Investigation of a New Tilidine/Naloxone Liquid Formulation Compared to a Reference Formulation"; Arzneim.-Forsch./Drug Res. (1999) Vol 49, pg. 599-607												
HS	HN	Martin, et al., "Demonstration of Tolerance to and Physical Dependence on N-allylnormorphine (Nalorphine)"; J. of Pharm and Exper Thera (1965) Vol 150, No. 3, pg. 437-442												
HS	HO	Mendelson, et al., "Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers"; Psychopharmacology (1999) Vol 141, pg. 37-46												
HS	HP	Mendelson, et al., "Buprenorphine and Naloxone Interactions in Methadone Maintenance Patients"; Society of Biological Psychiatry (1997) Vol 41, pg. 1095-1101												
HS	HQ	Nutt, et al., "Methadone-naloxone mixtures for use in methadone maintenance programs"; Clin Pharma and Thera, Vol 15, No. 2, pg. 156-166 (1974)												
HS	HR	Parwatikar, et al., "Methadone-naloxone in combination for the treatment of heroin addicts"; Clin Pharm and Thera, Vol 14, No. 6, pg. 941-948 (1973)												
EXAMINER  /Humera Sheikh/										DATE CONSIDERED  01/21/2007				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														



FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133		SERIAL NO.: <del>09781-081</del> 10/700,906								
LIST OF PRIOR ART CITED BY APPLICANT  (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.		FILING DATE: <del>February 8, 2001</del> 11/14/03								
				GROUP: 1615										
U.S. PATENT DOCUMENTS														
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
HS	IA	5	6	5	6	2	9	5	08/12/1997	Oshlack, et al.	424	468		
HS	IB	5	6	7	0	1	7	2	09/23/1997	Buxton, et al.	424	495		
HS	IC	5	6	7	2	3	6	0	09/30/1997	Sackler, et al.	424	490		
HS	ID	5	6	8	1	5	8	5	10/28/1997	Oshlack, et al.	424	494		
HS	IE	5	7	6	3	4	5	2	06/09/1998	Miller, et al.	514	282		
HS	IF	5	7	8	0	4	7	9	07/14/1998	Kim	514	282		
HS	IG	5	8	1	1	1	2	6	09/22/1998	Krishnamurthy	424	498		
HS	IH	5	8	3	4	4	7	7	11/10/1998	Mioduszewski	514	282		
HS	II	5	8	4	3	4	8	0	12/01/1998	Miller, et al.	424	484		
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	IJ													
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
HS	IK	Pärwartikar, et al., "Naloxone-Methadone Combination for the Treatment of Opiate Dependence"; Missouri Institute of Psychiatry, pg. 1350-1354 (1973)												
HS	IL	Pitts, et al., "Antinociceptive and Response Rate-Altering Effects of Kappa Opioid Agonists, Spiradoline, Enadoline and U69,593, Alone and in combination with Opioid Antagonists in Squirrel Monkeys"; J. Pharm and Exper Thera (1994) Vol 271, No. 3, pg. 1501-1508												
HS	IM	Preston, et al., "Buprenorphine and Naloxone alone and in combination in opioid-dependent humans"; Psychopharmacology (1988) Vol 94, pg. 484-490												
HS	IN	Preston, et al., "Differential Naltrexone Antagonism of Hydromorphone and Pentazocine Effects in Human Volunteers"; J. Pharm and Exper Thera (1993) Vol 264, No. 2, pg. 813-823												
HS	IO	Preston, et al., "Effects of Sublingually given naloxone in opioid-dependent human volunteers"; Drug and Alcohol Dependence (1990) Vol 25, pg. 27-34												
HS	IP	Bigelow, et al., "Abuse Liability Assessment of Buprenorphine-Naloxone Combinations"; Dept. of Psychiatry and Behavioral Sciences - The Johns Hopkins University School of Medicine, pg. 145-149 (2003)												
HS	IQ	Wikler, et al., 'N-Allylnormorphine: Effects of single doses and precipitation of acute "Abstinence Syndromes" during addiction to morphine, methadone or heroin in man (post-addicts); N-Allylnormorphine During Narcotic Addiction (1953) pg. 8-20												
EXAMINER  /Humera Sheikh/										DATE CONSIDERED  01/21/2007				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133		SERIAL NO.: <del>09/781,081</del> <b>10/700,906</b>	
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.			
				FILING DATE: <del>February 8, 2001</del> <b>10/04/03</b>		GROUP: 1615	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL	ID	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
HS	JA	5 8 4 9 2 4 0	12/15/1998	Miller, et al.	264	460	
HS	JB	5 8 6 9 0 9 7	02/09/1999	Wong, et al.	424	473	
HS	JC	5 8 7 9 7 0 5	03/09/1999	Heafield, et al.	424	464	
HS	JD	5 8 9 1 4 7 1	04/06/1999	Miller, et al.	424	468	
HS	JE	5 9 0 8 8 4 8	06/01/1999	Miller, et al.	514	282	
HS	JF	5 9 5 8 4 5 2	09/28/1999	Oshlack, et al.	424	457	
HS	JG	5 9 5 8 4 5 9	09/28/1999	Chasin, et al.	424	490	
HS	JH	5 9 6 5 1 6 1	10/12/1999	Oshlack, et al.	424	457	
HS	JI	5 9 6 5 1 6 3	10/12/1999	Miller, et al.	424	468	
HS	JJ	5 9 6 8 5 5 1	10/19/1999	Oshlack, et al.	424	456	
<b>FOREIGN PATENT DOCUMENTS</b>							
ID	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	JK						
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
HS	JL	Zaks, et al., "Naloxone Treatment of Opiate Dependence"; JAMA (1971) Vol 215, No. 13, pg. 2108-2110					
HS	JM	Barton, et al., "Intranasal Administration of Naloxone by Paramedics"; Prehospital Emergency Care (2002) Vol 6, No. 1, pg. 54-58					
HS	JN	Blachly, Paul, H., M.D., "Naloxone in Opiate Addiction"; Current Psychiatric Therapies (1976) pg. 209-213					
HS	JO	Bashaw, et al., "Relative bioavailability of controlled-release oral morphine sulfate during naltrexone blockade"; Inter J. of Clin Pharm and Thera (1995) Vol 33, No. 9, 524-529					
HS	JP	Jasinski, D.R., "Assessment of the Abuse Potentiality of Morphinelike Drugs (Methods Used in Man)"; Drug Addiction (1977) pg. 197-258					
HS	JQ	Johnson, et al., "Buprenorphine and Naloxone for Heroin Dependence"; Substance Use Disorders (2000) pg. 519-526					
HS	JR	Strain, et al., "Opioid antagonist effects of dezocine in opioid-dependent humans"; Clin Pharm and Thera (1996) Vol 60, No. 2, pg. 206-217					
EXAMINER				DATE CONSIDERED			
/Humera Sheikh/				01/21/2007			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133		SERIAL NO.: 097781,081 <u>10/700,906</u>		
LIST OF PRIOR ART CITED BY APPLICANT  (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.				
				FILING DATE: February 8, 2001 <u>11/04/03</u>		GROUP: 1615		
U.S. PATENT DOCUMENTS								
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
<div style="font-size: 2em;">↓</div>	KA	6 0 2 4 9 8 2	02/15/2000	Oshlack, et al.	424	476		
	KB	6 0 6 8 8 5 5	05/30/2000	Leslie, et al.	424	468		
	KC	6 0 7 7 5 3 2	06/20/2000	Malkowska, et al.	424	457		
	KD	6 0 7 7 5 3 3	06/20/2000	Oshlack, et al.	424	461		
	KE	6 1 0 3 2 5 8	08/15/2000	Simon.	424	449		
	KF	6 1 0 3 2 6 1	08/15/2001	Chasin, et al.	424	459		
	KG	6 1 4 3 3 2 2	11/07/2000	Sackler, et al.	424	459		
	KH	6 1 4 3 3 2 8	11/07/2000	Heafield, et al.	424	489		
	KJ	6 1 6 2 4 6 7	12/19/2000	Miller, et al.	424	468		
	KJ	6 2 1 0 7 1 4	04/03/2001	Oshlack, et al.	424	476		
	KK	6 2 5 4 8 8 7	07/03/2001	Miller, et al.	424	468		
	KL	6 2 6 1 5 9 9	07/17/2001	Oshlack, et al.	424	457		
	HS	KM	6 2 9 4 1 9 5	09/25/2001	Oshlack, et al.	424	457	
	FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
						YES	NO	
HS	KN	0 1 3 7 7 8 5	05/31/2001	WO (A2)	A61K			
HS	KO	0 1 5 2 8 5 1	07/26/2001	WO (A1)	A61K	31/485		
HS	KP	0 1 8 5 2 5 7	11/15/2001	WO (A2)	A61P			
HS	KQ	0 1 9 3 8 5 2	12/13/2001	WO (A2)	A61K	31/00		
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)								
HS	KR	Preston, et al., "Abuse liability studies of opioid agonist-antagonists in humans"; Drug and Alcohol Dependence (1991) Vol 28, pg. 49-82						
HS	KS	Brennscheidt, et al., "Pharmacokinetics of Nortilidine and Naloxone after Administration of Tilidine/Naloxone Solution or Tilidine/Naloxone Sustained Release Tablets"; Arzneim.-Forsch/Drug Res. (2000) Vol 50, pg. 1015-1022						
EXAMINER:  /Humera Sheikh/				DATE CONSIDERED 01/21/2007				
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>								

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133		SERIAL NO.: <del>09781,081</del> 10/700,906									
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.											
				FILING DATE: <del>February 8, 2001</del> 11/04/03		GROUP: 1615									
<b>U.S. PATENT DOCUMENTS</b>															
*EXAMINER INITIAL		DOCUMENT NUMBER								DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
HS	LA	6	3	0	6	4	3	8	10/23/2001	Oshlack, et al.	424	468			
HS	LB	6	3	2	6	0	2	7	12/04/2001	Miller, et al.	424	468			
HS	LC	6	3	3	5	0	3	3	01/01/2002	Oshlack, et al.	424	457			
HS	LD	6	3	7	5	9	5	7	04/23/2002	Kaiko, et al.	424	400			
HS	LE	6	3	8	7	4	0	4	05/14/2002	Oshlack, et al.	424	480			
HS	LF	6	3	9	9	0	9	6	06/04/2002	Miller, et al.	424	464			
HS	LG	6	4	7	5	4	9	4	11/05/2002	Kaiko, et al.	424	400			
<b>FOREIGN PATENT DOCUMENTS</b>															
		DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
														YES	NO
	LH														
	LI														
	LJ														
	LK														
	LL														
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>															
	LM														
	LN														
	LO														
	LP														
EXAMINER                      /Humera Sheikh/											DATE CONSIDERED              01/21/2007				
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>															

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY. DOCKET NO.: 200.1133		SERIAL NO.: <del>09/781,981</del> 10/700,906							
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> (Use several sheets if necessary)						APPLICANT(S): Curtis Wright et al.									
						FILING DATE: February 8, 2001 11/04/03		GROUP: 1615							
<b>U.S. PATENT DOCUMENTS</b>															
*EXAMINE R INITIAL	AA	DOCUMENT NUMBER								DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
HS	AA	5	9	9	8	4	3	4	12/99	Mitch et al.	514	210.16			
	AB	5	9	7	2	9	5	4	10/99	Foss	514	282			
	AC	5	9	6	8	5	4	7	10/99	Reder et al.	424	449			
	AD	5	9	4	2	2	4	1	8/99	Chasin et al.	424	426			
	AE	5	8	8	0	1	3	2	3/99	Hill	514	282			
	AF	5	8	6	6	1	6	4	2/99	Kuczynski et al.	424	472			
	AG	5	8	6	0	9	5	0	1/99	Demopoulos et al.	604	49			
	AH	5	8	5	8	0	1	7	1/99	Demopoulos et al.	604	890.1			
	AI	5	7	6	7	1	2	5	6/98	Crain et al.	514	282			
↓	AJ	5	6	3	3	2	5	9	5/97	Qin et al.	514	282			
HS	AK	5	6	2	4	9	3	2	4/97	Qin et al.	514	282			
<b>FOREIGN PATENT DOCUMENTS</b>															
		DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
														YES	NO
HS	AL	19	6	5	1	5	5	1	6/98	DE	A61K	31/485			
HS	AM	29	7	1	9	7	0	4	2/97	DE	A61K	31/485			
HS	AN	4	3	2	5	4	6	5	2/95	DE	A61K	31/485	X		
HS	AO	2	2	2	2	0	3	9	11/72	DE	A61K	27/00			
HS	AP	0	9	1	3	1	5	2	6/99	EP	A61K	31/485			
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>															
HS	AQ	Abstract, Cancer Chemother Pharmacol (1998); 42(4):287-91.													
HS	AR	Yuan et al., Drug and Alcohol Dependence (1998); 52:161-165.													
HS	AS	Gan et al., "Opioid-Sparing Effects of a Low-Dose Infusion of Naloxone in Patient-Administered Morphine Sulfate," Anesthesiology (1997), 87(5):1075-1080.													
EXAMINER  /Humera Sheikh/										DATE CONSIDERED  01/21/2007					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.															



FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133		SERIAL NO.: 09/781,081 <u>10/700,806</u>								
LIST OF PRIOR ART CITED BY APPLICANT  (Use several sheets if necessary)				APPLICANT(S): Curtis Wright et al.										
				FILING DATE: February 8, 2001 <u>11/04/03</u>		GROUP: 1615								
U.S. PATENT DOCUMENTS														
*EXAMINER INITIAL	CA	DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
HS	CA	5	4	7	2	9	4	3	12/95	Crain et al.	514	12		
	CB	5	4	5	7	2	0	8	10/95	Portoghese et al.	546	35		
	CC	5	4	2	6	1	1	2	6/95	Zagon et al.	514	282		
	CD	5	3	7	6	6	6	2	12/94	Ockert	514	282		
	CE	5	3	5	6	9	0	0	10/94	Bihari et al.	514	282		
	CF	5	3	5	2	6	8	3	10/94	Mayer et al.	514	289		
	CG	5	3	5	2	6	8	0	10/94	Portoghese et al.	514	279		
	CH	5	3	2	1	0	1	2	6/94	Mayer et al.	514	25		
	CI	5	3	1	7	0	2	2	5/94	Borsodi et al.	514	282		
	CJ	5	3	1	6	7	5	9	5/94	Rose et al.	424	10		
HS	CK	5	2	7	3	7	6	0	12/93	Oshlack et al.	424	486		
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
HS	CL	9	7	3	3	5	6	6	9/97	WO	A61K	9/20		
HS	CM	9	6	0	2	2	5	1	2/96	WO	A61K	31/485		
HS	CN	9	5	0	3	8	0	4	2/95	WO	A61K	31/485		
HS	CO	9	4	0	6	4	2	6	3/94	WO	A61K	31/46		
HS	CP	8	3	0	3	1	9	7	9/83	WO	A61K	9/22		
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
HS	CQ	Mendelson J., et al., "Buprenorphine and Naloxone Interactions in Opiate-Dependent Volunteers," Clin. Phar. Ther. (1996), 60:105-114.												
HS	CR	Walsh et al., "Effects of Naltrexone on Response to Intravenous Cocain, Hydromorphone and their Combination in Humans," (1996).												
EXAMINER      /Humera Sheikh/										DATE CONSIDERED      01/21/2007				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY. DOCKET NO.: 200.1133		SERIAL NO.: <del>09/781,081</del> 10/700,906	
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> (Use several sheets if necessary)						APPLICANT(S): Curtis Wright et al.			
						FILING DATE: February 8, 2004 11/04/03		GROUP: 1615	
<b>U.S. PATENT DOCUMENTS</b>									
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE			
<div style="font-size: 2em;">↓</div>	DA	5 2 5 6 6 6 9	10/93	Askanazi et al.	514	282			
	DB	5 2 3 6 7 1 4	8/93	Lee et al.	424	449			
	DC	5 2 2 5 4 4 0	7/93	London et al.	514	535			
	DD	5 1 4 9 5 3 8	9/92	Granger et al.	424	449			
	DE	5 1 0 2 8 8 7	4/92	Goldberg	514	282			
	DF	5 0 9 6 7 1 5	3/92	Sinclair	424	449			
	DG	5 0 8 6 0 5 8	2/92	Sinclair et al.	514	282			
	DH	5 0 7 5 3 4 1	12/91	Mendelson et al.	514	282			
	DI	4 9 3 5 4 2 8	6/90	Lewis	514	282			
	DJ	4 8 8 9 8 6 0	12/89	Rzeszotarski et al.	514	282			
HS	DK	4 8 8 2 3 3 5	11/89	Sinclair	514	282			
<b>FOREIGN PATENT DOCUMENTS</b>									
DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION				
					YES	NO			
DL									
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>									
HS	DM	Chih-Cheng Chian, Neuroscience Letters 190 (1995), 137-139.							
HS	DN	Crain et al., "Ultra-Low Concentrations of Naloxone Selectively Antagonize Excitatory Effects of Morphine on Sensory Neurons, Thereby Increasing Its Antinociceptive Potency and Attenuating Tolerance/Dependence During Chronic Cotreatment," Proc. Natl. Acad. Sci. USA (1995), 92:10540-10544.							
HS	DO	Hanson, Analgesic, Antipyretic and Anti-Inflammatory Drugs in Remington's Science and Practice of Pharmacy (1995), 2:1207.							
HS	DP	Physician's Desk Reference 48 <sup>th</sup> Ed. (1994) Montvale, NJ, 2120-2121.							
HS	DQ	Foss et al., J. Clin Pharmacol (1993), 33:747-751.							
EXAMINER /Humera Sheikh/				DATE CONSIDERED 01/21/2007					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									



FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133		SERIAL NO.: <del>09781.081</del> 10/700,906									
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Curtis Wright et al.											
				FILING DATE: <del>February 8, 2004</del> 11/04/03		GROUP: 1615									
U.S. PATENT DOCUMENTS															
*EXAMINER INITIAL	CLASS	DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
HS	EA	4	8	7	3	0	7	6	10/89	Fishman et al.	412	10			
	EB	4	8	6	1	7	8	1	8/89	Goldberg	514	282			
	EC	4	8	6	1	5	9	8	8/89	Oshlack et al.					
	ED	4	8	0	6	5	5	8	2/89	Wuest et al.	514	381			
	EE	4	8	0	6	5	4	3	2/89	Choi	514	464			
	EF	4	8	0	6	3	4	1	2/89	Chien et al.	424	448			
	EG	4	8	0	3	2	0	8	2/89	Pasternak	514	282			
	EH	4	7	8	5	0	0	0	11/88	Kreek et al.	514	282			
	EI	4	7	6	9	3	7	2	9/88	Kreek et al.	514	282			
	EJ	4	7	6	0	0	6	9	7/88	Rzeszotarski et al.	514	282			
HS	EK	4	7	3	0	0	4	8	3/88	Portoghese et al.	546	45			
FOREIGN PATENT DOCUMENTS															
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO		
	EL														
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)															
HS	EM	Holmes et al., Anesth. Analg. (1993), 77:1166-73.													
HS	EN	Miaskowski et al., Brain Research (1992), 596:41-45.													
HS	EO	Weinhold et al., "Buprenorphine Alone and In Combination with Naltrexone in Non-Dependent Humans," Drug and Alcohol Dependence (1992), 30:263-274.													
HS	EP	Cappel et al., Pharma. Bioch. & Behav. (1989), 34:425-427.													
HS	EQ	Vaccarino et al., Pain (1989), 36:103-109.													
HS	ER	Gonzalez et al., "Naltrexone: A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Efficacy in the Management of Opioid Dependence," Drugs (1988), 35:192-213.													
EXAMINER /Humera Sheikh/										DATE CONSIDERED 01/21/2007					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.															

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133		SERIAL NO.: <del>09/781,081</del> 10/700,906								
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> (Use several sheets if necessary)				APPLICANT(S): Curtis Wright et al.										
				FILING DATE: <del>February 8, 2004</del> 11/04/03		GROUP: 1615								
<b>U.S. PATENT DOCUMENTS</b>														
*EXAMINER INITIAL	FA	4	7	1	9	2	1	5	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
HS	FA	4	7	1	9	2	1	5	1/88	Goldberg	514	282		
	FB	4	6	6	1	4	9	2	4/87	Lewis et al.	514	282		
	FC	4	6	0	8	3	7	6	8/86	Pasternak	514	282		
	FD	4	5	8	2	8	3	5	4/86	Lewis et al.	514	282		
	FE	4	5	7	3	9	9	5	3/86	Chen et al.	604	896		
	FF	4	4	6	4	3	7	8	8/84	Hussain et al.	424	260		
	FG	4	4	5	7	9	3	3	7/84	Gordon et al.	424	260		
	FH	4	4	5	1	4	7	0	5/84	Ganti	424	260		
	FI	4	4	0	1	6	7	2	8/83	Portoghese et al.	424	260		
↓	FJ	4	1	7	6	1	8	6	11/79	Goldberg	424	260		
HS	FK	3	9	6	6	9	4	0	6/76	Pachter et al.	424	260		
<b>FOREIGN PATENT DOCUMENTS</b>														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	FL													
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>														
HS	FM	Sunshine, et al., "Analgesic Efficacy of Pentazocine Versus a Pentazocine-Naloxone Combination Following Oral Administration," Clin. J. Pain (1988), 4:35-40.												
HS	FN	Wang et al., "Crossover and Parallel Study of Oral Analgesics," J. clin. Pharmacol (1981), 21:162-168.												
	FO													
	FP													
	FQ													
	FR													
EXAMINER /Humera Sheikh/										DATE CONSIDERED 01/21/2007				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY. DOCKET NO.: 200.1133		SERIAL NO.: <del>09/781,081</del> 16/700,906						
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> (Use several sheets if necessary)						APPLICANT(S): Curtis Wright et al.								
						FILING DATE: <del>February 8, 2004</del> 11/04/03				GROUP: 1615				
<b>U.S. PATENT DOCUMENTS</b>														
*EXAMINER INITIAL	CLASS	DOCUMENT-NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
HS	GA	3	8	7	9	5	5	5	4/75	Pachter et al.	424	260		
HS	GB	3	7	7	3	9	5	5	11/73	Pachter et al.	424	260		
HS	GC	3	6	7	6	5	5	7	7/72	Lachman et al.	424	260		
HS	GD	3	4	9	3	6	5	7	2/70	Lewenstein et al.	424	260		
HS	GE	3	3	3	2	9	5	0	7/67	Blumberg et al.	260	285		
HS	GF	2	7	7	0	5	6	9	11/56	Fromherz et al.	167	65		
	GG													
	GH													
	GI													
	GJ													
	GK													
<b>FOREIGN PATENT DOCUMENTS</b>														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	GL													
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>														
	GM													
	GN													
	GO													
	GP													
	GQ													
	GR													
	GS													
EXAMINER  /Humera Sheikh/										DATE CONSIDERED  01/21/2007				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

## LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): Curtis WRIGHT, et al.

FILING DATE: February 8,  
2001 11/04/03

GROUP: 1615

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER								DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
HS	AA	6	2	2	8	8	6	3		05/08/01	Palermo et al.	514	282	
HS	AB	6	2	7	7	3	8	4		08/21/01	Kaiko et al.	424	400	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
														YES	NO
HS	AC	WO	98	2	5	6	1	3		06/18/98	EPO	A61K	31/485	Abstract	
HS	AD	WO	00	3	8	6	4	9		07/06/00	EPO	A61K	9/00	Abstract	

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

HS	AE	Press Release entitled "International Patent Application To Be Published on Abuse-Resistant Pain Reliever Being Developed by Purdue Pharma" August 8, 2001.												
HS	AF	Paronis, et al., Increased Analgesic Potency of Mu Agonists after Continuous Naloxone Infusion in Rats, J Pharm. Exper. Ther. 1991 259(2) pg 582-589												
HS	AG	Yoburn, et al., Supersensitivity to Opioid Analgesics Following Chronic Opioid Antagonist Treatment: Relationship to Receptor Selectivity, Pharmacol. Bio. Beh. 1995 51 (2) pg 535-539												
HS	AH	Crain, et al., Acute thermal hyperalgesia elicited by low-dose morphine in normal mice is blocked by ultra-low-dose naltrexone, unmasking potent opioid analgesia, Brain Res. 2001 888 pg 75-82												
HS	AI	Zhang, et al., Down-Regulation of $\mu$ -Opioid Receptors in Rat and Monkey Dorsal Root Ganglion Neurons and Spinal Cord After Peripheral Axotomy, Neuroscience 1998 82, pg 223-240												
HS	AJ	Abdulla, et al., Axotomy reduces the effect of analgesic opioids yet increases the effect of nociceptin on dorsal root ganglion neurons, J. Neuro Sci 1998 18, pg 9685-9694												
HS	AK	Di Giannuario, et al., Orphanin FQ reduces morphine-induced dopamine release in the nucleus accumbens: a microdialysis study in rats, Neurosci. Lett. 1999 272, pg 183-186												
HS	AL	Ciccocioppo, et al., Effect of nociceptin/orphanin FQ on the rewarding properties of morphine, Eur. J. Pharmacol. 2000 404, pg 153-159												
	AM													
	AN													

EXAMINER

/Humera Sheikh/ 01/21/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133		SERIAL NO.: 09781-081 <i>10/700,906</i>	
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> (Use several sheets if necessary)				APPLICANT(S): Curtis WRIGHT, et al.			
				FILING DATE: February 8, 2001 <i>11/04/03</i>		GROUP: 1615	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
HS	AA	Benfey, Function of Myocardial $\alpha$ -ADRENOCEPTORS: Life Sciences (1982) Vol. 31 pg 101-112					
HS	AB	Levine, et al., Potentiation of Pentazocine Analgesia by Low-dose Naloxone: J. Clin. Invest. (1988) Vol. 82 pg. 1574-1577					
HS	AC	Yoburn, et al., Opioid Antagonist-induced Receptor Upregulation: Effects of Concurrent Agonist Administration, (1994) (Publication Date): Brain Research Bulletin, Vol. 33 pg 237-240					
HS	AD	Bunzow, et al., Molecular cloning and tissue distribution of a putative member of the rat opioid receptor gene family that is not a $\mu$ , $\delta$ or $\kappa$ opioid receptor type: FEBS Letters 347 (1994) pg. 284-288					
HS	AE	Mollereau, et al., ORL1, a novel member of the opioid receptor family: Cloning, functional expression and localization: FEBS Letters 341 (1994) pg. 33-38					
HS	AF	Wang, et al., cDNA cloning of an orphan opiate receptor gene family member and its splice variant: FEBS Letters 348 (1994) 75-79					
HS	AG	Suzuki, et al., Morphine conditioned place preference after chronic treatment with naloxone in the rat: Research Communications in Substances of Abuse. (1991) Vol. 12, No. 3 pg. 119-131					
EXAMINER  /Humera Sheikh/				DATE CONSIDERED 01/21/2007			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:  
200.1133CON5SERIAL NO.:  
10/700,906

 LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S):  
Benjamin OSHLACK et al.FILING DATE:  
November 4, 2003GROUP:  
~~To be assigned~~ 16/5

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
HS	AA	4	5	8	7	1	1	8	05/06/1986	Hsiao	424	459	
	AB												
	AC												
	AD												
	AE												
	AF												
	AG												

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
HS	AH	04	0	5	2	3	4	6	06/24/04	WO (A1)	A61K	9/62		
HS	AI	0	5	4	8	4	4	8	09/06/2000	EP (B1)	A61K	9/50	abstract	
	AJ													
	AK													
	AL													

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AM	
	AN	
	AO	
	AP	
	AQ	
	AR	
	AS	

EXAMINER /Humera Sheikh/

DATE CONSIDERED 01/21/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:  
200.1133CON5SERIAL NO.:  
10700,906

## LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S):  
Benjamin OSHLACK et al.FILING DATE:  
November 4, 2003GROUP:  
1615

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
HS	AH	1 3 9 0 7 7 2	04/16/1975	GB	A61K31	485		
	AI							
	AJ							
	AK							
	AL							

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AM	
	AN	
	AO	
	AP	
	AQ	
	AR	
	AS	

EXAMINER

/Humera Sheikh/

DATE CONSIDERED

01/21/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.